News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Jun 1, 2022

Summary Toggle aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO , June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S.
May 17, 2022

Summary Toggle aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis patients.
May 16, 2022

Summary Toggle aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis

Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery
May 13, 2022

Summary Toggle aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the Compensation Committee of aTyr’s Board of
May 10, 2022

Summary Toggle aTyr Pharma to Present at Upcoming Investor Conferences in May

SAN DIEGO , May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the company will present at two upcoming investor
May 9, 2022

Summary Toggle aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update

Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022.
May 2, 2022

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results

Management to host conference call and webcast on May 9th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today
Apr 13, 2022

Summary Toggle aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis

Second U.S. orphan drug designation for efzofitimod clinical program SAN DIEGO , April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today
Apr 11, 2022

Summary Toggle aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting

Findings suggest that ATYR2810 reduces metastasis and enhances chemosensitivity by downregulating key genes linked to these processes. SAN DIEGO , April 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative
Apr 1, 2022

Summary Toggle aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis patients.